An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

NCT04148287 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Candidemia
Invasive Candidiases
Candida Infection

Interventions

DRUG: APX001

Sponsor

Basilea Pharmaceutica